{"id":476391,"date":"2020-03-26T13:12:01","date_gmt":"2020-03-26T13:12:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476391"},"modified":"2020-03-26T13:12:01","modified_gmt":"2020-03-26T13:12:01","slug":"neuroendocrine-tumors-nets-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/neuroendocrine-tumors-nets-epidemiology-forecast-to-2030_476391.html","title":{"rendered":"Neuroendocrine Tumors (NETs) Epidemiology Forecast to 2030"},"content":{"rendered":"
\"Neuroendocrine<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Neuroendocrine Tumors (NETs) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Neuroendocrine Tumors (NETs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n

DelveInsight<\/strong> launched a new report on Neuroendocrine Tumors (NETs) – Epidemiology Forecast to 2030<\/a><\/p>\n

DelveInsight’s ‘Neuroendocrine Tumors (NETs) – Epidemiology Forecast to 2030<\/strong>‘ report delivers an in-depth understanding of the disease, historical and forecasted Neuroendocrine Tumors (NETs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

The key facts of the report:<\/strong><\/p>\n

“The higher Neuroendocrine Tumor prevalent cases in the United States with 193,877 prevalent cases in 2016, followed by EU5 and Japan.”<\/strong><\/p>\n

\"\"<\/strong><\/p>\n

Request for sample pages<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/neuroendocrine-tumors-nets-epidemiology-forecast<\/p>\n

Scope of the report:<\/strong>
1. The Neuroendocrine Tumors (NETs) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
2. The Neuroendocrine Tumors (NETs) Epidemiology Report and Model provide an overview of the risk factors and global trends of Neuroendocrine Tumors (NETs) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
3. The report provides insight about the historical and forecasted patient pool of Neuroendocrine Tumors (NETs) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
4. The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
5. The report assesses the disease risk and burden and highlights the unmet needs of Neuroendocrine Tumors (NETs)
6. The report provides the segmentation of the Neuroendocrine Tumors (NETs) epidemiology<\/p>\n

Reasons to buy:
<\/strong>1. <\/strong>The Neuroendocrine Tumors (NETs) Epidemiology report will allow the user to –
2. Develop business strategies by understanding the trends shaping and driving the global Neuroendocrine Tumors (NETs) market
3. Quantify patient populations in the global Neuroendocrine Tumors (NETs) market to improve product design, pricing, and launch plans
4. Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Neuroendocrine Tumors (NETs) therapeutics in each of the markets covered
5. Understand the magnitude of Neuroendocrine Tumors (NETs) population by its epidemiology
6. The Neuroendocrine Tumors (NETs) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources<\/p>\n

Table of contents:<\/strong>
1. Key Insights 
2. Executive Summary of Neuroendocrine Tumors (NETs)
3. Neuroendocrine Tumors (NETs): Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9.  Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight<\/p>\n

Related reports:<\/strong><\/p>\n

Neuroendocrine Carcinoma – Epidemiology Forecast to 2030<\/a><\/p>\n

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) – Epidemiology Forecast to 2030<\/a> <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Yash Bhardwaj
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s ‘Neuroendocrine Tumors (NETs) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Neuroendocrine Tumors (NETs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-476391","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=476391"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476391\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=476391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=476391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=476391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}